# HUMA catalysts: Humacyte, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/huma/catalysts

> Humacyte, Inc. (HUMA) has 6 upcoming catalysts. The next is the acellular tissue engineered vessel (atev) primary completion, June 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Humacyte, Inc. |
| Ticker | HUMA (Nasdaq) |
| SEC CIK | 1818382 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/huma |

## Cash runway

Cash $64.5M as of 2026-09-30; quarterly burn $15.0M; about 12.9 months of runway at that rate (XBRL company facts, accession 0001193125-26-455588).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2023 | [Vascular topline data readout](https://sec-api.dev/pdufa/vascular) | HUMA |  | completed, positive | "In September 2023, we announced positive topline results from our V005 Phase 2/3 trial in vascular trauma, and in December 2023, we filed a BLA for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1818382/000119312526347022/huma-20260630.htm)) |
| Sep 2023 | [Vascular NDA/BLA submission](https://sec-api.dev/pdufa/vascular) | HUMA |  | completed | "In September 2023, we announced positive topline results from our V005 Phase 2/3 trial in vascular trauma, and in December 2023, we filed a BLA for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1818382/000119312526347022/huma-20260630.htm)) |
| December 12, 2023 | [Vascular NDA/BLA submission](https://sec-api.dev/pdufa/vascular) | HUMA |  | completed | "For example, on December 12, 2023, we submitted our BLA for the ATEV in urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated and autologous vein use is not feasible." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/huma-20251231.htm)) |
| Feb 2024 | [Vascular NDA/BLA acceptance](https://sec-api.dev/pdufa/vascular) | HUMA |  | completed | "In February 2024, the FDA accepted our BLA in the vascular trauma indication and granted priority review of that BLA." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/huma-20251231.htm)) |
| Jul 2024 | [Humacyte, Inc. topline data readout](https://sec-api.dev/companies/huma/catalysts) | HUMA |  | completed, met | "In July 2024, we announced positive topline results from our V007 Phase 3 trial of the ATEV for use in AV access, where the ATEV met the primary endpoints in the study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1818382/000119312526347022/huma-20260630.htm)) |
| August 10, 2024 | [Symvess (symvess) PDUFA date](https://sec-api.dev/pdufa/symvess) | HUMA |  | scheduled | "Although our original PDUFA date was August 10, 2024, the FDA took an additional 19 weeks to complete its review of the risks and benefits of Symvess." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818382/000110465925028830/tm2510708d1_ex99-1.htm)) |
| Dec 2024 | [LUNA200 FDA approval](https://sec-api.dev/pdufa/luna200) | HUMA |  | completed, approved | "FDA approved Symvess (ATEV ) BLA in December 2024 for treatment of extremity vascular trauma; U.S. market launch commenced Q1 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818382/000110465925027762/tm258849d2_ex99-1.htm)) |
| December 19, 2024 | [Vascular FDA approval](https://sec-api.dev/pdufa/vascular) | HUMA |  | completed, approved | "We received our first FDA approval of the ATEV on December 19, 2024, a full approval for Symvess (acellular tissue engineered vessel-tyod) for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/huma-20251231.htm)) |
| December 19, 2024 | [Symvess (symvess) FDA approval](https://sec-api.dev/pdufa/symvess) | HUMA | Extremity Vascular Trauma | completed, approved | "Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818382/000181838224000227/huma-20241219xexx991.htm)) |
| March 28, 2025 | [Humacyte, Inc. earnings report](https://sec-api.dev/companies/huma/catalysts) | HUMA |  | completed | "Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818382/000181838225000030/huma-20250328xexx991.htm)) |
| May 13, 2025 | [Humacyte, Inc. earnings report](https://sec-api.dev/companies/huma/catalysts) | HUMA |  | completed | "Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818382/000181838225000073/huma-20250513xexx991.htm)) |
| August 11, 2025 | [Humacyte, Inc. earnings report](https://sec-api.dev/companies/huma/catalysts) | HUMA |  | completed | "Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818382/000181838225000122/huma-20250811xexx991.htm)) |
| November 12, 2025 | [Humacyte, Inc. earnings report](https://sec-api.dev/companies/huma/catalysts) | HUMA |  | completed | "Announces Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818382/000110465925109718/tm2530973d1_ex99-1.htm)) |
| Q2 2026 | [Humacyte, Inc. topline data readout](https://sec-api.dev/companies/huma/catalysts) | HUMA |  | scheduled | "The 80th patient from V012 is expected to complete one year of follow up in April 2026 and we expect to report top-line interim results from the trial in the second quarter of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/huma-20251231.htm)) |
| June 10, 2026 | [Humacyte, Inc. topline data readout](https://sec-api.dev/companies/huma/catalysts) | HUMA |  | completed, positive | "On June 10, 2026, we announced positive top-line interim results for our V012 Phase 3 clinical trial of the ATEVs in female patients with end-stage kidney disease ("ESKD") requiring hemodialysis access." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1818382/000110465926072961/tm2616944-3_424b5.htm)) |
| August 12, 2026 | [Humacyte, Inc. earnings report](https://sec-api.dev/companies/huma/catalysts) | HUMA |  | completed | "Announces Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818382/000110465926094440/tm2622949d1_ex99-1.htm)) |
| Nov 2026 | [Clopidogrel NDA/BLA submission](https://sec-api.dev/pdufa/clopidogrel) | HUMA |  | scheduled | ""In our future targeted market in dialysis access, our plan is to file a supplemental BLA for the ATEV in November 2026, supported by results from three Phase 3 studies." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818382/000119312526454402/huma-ex99_1.htm)) |
| November 10, 2026 | [Symvess (symvess) earnings report](https://sec-api.dev/pdufa/symvess) | HUMA |  | completed | "Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818382/000119312526454402/huma-ex99_1.htm)) |
| June 2027 | [Acellular tissue engineered vessel (atev) primary completion](https://sec-api.dev/pdufa/acellular-tissue-engineered-vessel-atev) | HUMA | End Stage Renal Disease (ESRD) | scheduled | "NCT05908084 (To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Humacyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05908084)) |
| Jun to Sep 2027 | [Acellular tissue engineered vessel (atev) topline data readout](https://sec-api.dev/pdufa/acellular-tissue-engineered-vessel-atev) | HUMA | End Stage Renal Disease (ESRD) | scheduled | "NCT05908084 (To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Humacyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05908084)) |
| December 2028 | [Acellular tissue engineered vessel (symvess) primary completion](https://sec-api.dev/pdufa/acellular-tissue-engineered-vessel-symvess) | HUMA | Vascular Trauma; Arterial Injury; Arterial Bleeding | scheduled | "NCT07762313 (An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury.): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Humacyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07762313)) |
| Dec 2028 to Mar 2029 | [Acellular tissue engineered vessel (symvess) topline data readout](https://sec-api.dev/pdufa/acellular-tissue-engineered-vessel-symvess) | HUMA | Vascular Trauma; Arterial Injury; Arterial Bleeding | scheduled | "NCT07762313 (An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury.): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Humacyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07762313)) |
| September 2030 | [Humacyte coronary tissue engineered vessel (ctev) primary completion](https://sec-api.dev/pdufa/humacyte-coronary-tissue-engineered-vessel-ctev) | HUMA | Coronary Artery Disease | scheduled | "NCT07730528 (Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2030-09 (ESTIMATED); Lead Sponsor Humacyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07730528)) |
| Sep to Dec 2030 | [Humacyte coronary tissue engineered vessel (ctev) topline data readout](https://sec-api.dev/pdufa/humacyte-coronary-tissue-engineered-vessel-ctev) | HUMA | Coronary Artery Disease | scheduled | "NCT07730528 (Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2030-09 (ESTIMATED); Lead Sponsor Humacyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07730528)) |

## Drugs

- [Acellular tissue engineered vessel (atev)](https://sec-api.dev/pdufa/acellular-tissue-engineered-vessel-atev): End Stage Renal Disease (ESRD)
- [Acellular tissue engineered vessel (symvess)](https://sec-api.dev/pdufa/acellular-tissue-engineered-vessel-symvess): Vascular Trauma
- [Clopidogrel](https://sec-api.dev/pdufa/clopidogrel): 
- [Humacyte coronary tissue engineered vessel (ctev)](https://sec-api.dev/pdufa/humacyte-coronary-tissue-engineered-vessel-ctev): Coronary Artery Disease
- [LUNA200](https://sec-api.dev/pdufa/luna200): 
- [Symvess (symvess)](https://sec-api.dev/pdufa/symvess): extremity vascular trauma
- [Vascular](https://sec-api.dev/pdufa/vascular): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/huma/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "HUMA catalysts: Humacyte, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/huma/catalysts

```bibtex
@misc{secapidev_companies_huma_catalysts_20261116,
  title        = {HUMA catalysts: Humacyte, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/huma/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_huma_catalysts_20261116","title":"HUMA catalysts: Humacyte, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/huma/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
